



(51) International Patent Classification:

C07K 16/46 (2006.01) C07K 16/28 (2006.01)
A61K 35/14 (2015.01) C07K 19/00 (2006.01)
A61K 35/17 (2015.01) C12N 15/13 (2006.01)
A61P 37/02 (2006.01) C12N 15/62 (2006.01)
A61P 37/06 (2006.01) C12N 5/0783 (2010.01)
C07K 14/705 (2006.01) C12N 5/10 (2006.01)

(21) International Application Number:

PCT/CA2018/051167

(22) International Filing Date:

19 September 2018 (19.09.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/560,574 19 September 2017 (19.09.2017) US
62/692,386 29 June 2018 (29.06.2018) US

(71) Applicants: **THE UNIVERSITY OF BRITISH COLUMBIA** [CA/CA]; University-Industry Liaison Office, #103-6190 Agronomy Road, Vancouver, British

Columbia V6T 1Z3 (CA). **CENTRE FOR DRUG RESEARCH AND DEVELOPMENT** [CA/CA]; 2405 Westbrook Mall, Fourth Floor, Vancouver, British Columbia V6T 1Z3 (CA).

(72) Inventors: **LEVINGS, Megan**; 3435 West 15th Avenue, Vancouver, British Columbia V6R 2Z2 (CA). **ORBAN, Paul**; 3435 West 15th Avenue, Vancouver, British Columbia V6R 2Z2 (CA). **DAWSON, Nicholas**; 304-995 West 59th Avenue, Vancouver, British Columbia V6P 6Z2 (CA). **LAMARCHE, Caroline**; 703-456 Moberly Avenue, Vancouver, British Columbia V5Z 4L7 (CA). **BERGQVIST, Jan Peter**; 315-2255 Cypress Street, Vancouver, British Columbia V6J 3M6 (CA).

(74) Agent: **SMART & BIGGAR**; 2300-1055 West Georgia Street, PO Box 11115, Vancouver, British Columbia V6E 3P3 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

(54) Title: ANTI-HLA-A2 ANTIBODIES AND METHODS OF USING THE SAME




Fig. 9

(57) Abstract: Provided are humanized anti-HLA-A2 antibodies. In certain aspects, the humanized anti-HLA-A2 antibodies are capable of constituting an antigen binding domain of a chimeric antigen receptor (CAR), where the CAR is capable of being expressed in a human cell such that the CAR specifically binds to HLA-A2. Also provided are CARs that include the humanized anti-HLA-A2 antibodies. Modified cells including the antibodies and CARs, as well as methods of using such modified cells are also provided.

[Continued on next page]

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*